- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Progressive multifocal leukoencephalopathy risk increases with longer natalizumab exposure
Forty-two cases of progressive multifocal leukoencephalopathy (PML) in patients receiving the humanized monoclonal antibody natalizumab have been documented since 2006 from MedWatch reports.
Key Points
Forty-two cases of progressive multifocal leukoencephalopathy (PML) in patients receiving the humanized monoclonal antibody natalizumab have been documented since 2006 from MedWatch reports.
The incidence of natalizumab-associated PML increases "with duration of [natalizumab] exposure during the first 3 years, after which it appears to stabilize," said David B. Clifford, MD, at the 62nd annual meeting of the American Academy of Neurology, Toronto.
To characterize the PML presenting in natalizumab-treated patients with multiple sclerosis (MS), he reviewed 24 cases from MedWatch records, published reports, and contacted many of the treating physicians involved. To estimate risk, data on the population exposed to natalizumab were obtained from Biogen Idec.
The risk of PML increased with duration of exposure through the first 3 years of treatment: the incidence was .035/1,000 patients with 1 to 12 infusions, increasing to 0.34/1,000 with 13 to 24 infusions, and 1.34/1,000 with 25 to 36 infusions.
Of the 42 cases of PML documented since 2006, 64% have occurred in Europe and 36% in the United States. The reasons for this difference are unknown, although it may be related to differences in prior therapies, Dr Clifford said. About 50% of PML cases had prior chemotherapy exposure both in the United States and Europe.
Ten of the 42 patients who developed PML as a result of natalizumab have died to date. Immune reconstitution with plasma exchange is the only effective treatment for natalizumab-associated PML, given natalizumab's long half-life, but plasma exchange comes at a cost of immune reconstitution inflammatory syndrome (IRIS), which is recognized by progression of MS symptoms and signs, and evolution of MS lesions.
As evidence of lesion evolution as a part of IRIS, "natalizumab-associated PML lesions had Gd+ enhancement on T1 images in 15 of the 42 cases at diagnosis," making it difficult to distinguish PML from exacerbations of MS, said Dr Clifford.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
